Admission visfatin levels predict pancreatic and peripancreatic necrosis in acute pancreatitis and correlate with clinical severity

American Journal of Gastroenterology

Volumn 106, Issue 5, 2011, Pages 957-967

  Schäffler, Andreas ^a   Hamer, Okka Wilkea ^a   Dickopf, Judith ^a   Goetz, Andrea ^a   Landfried, Karin ^a   Voelk, Markus ^a   Herfarth, Hans ^b   Kopp, Andrea ^a   Buechler, Christa ^a   Schölmerich, Jürgen ^a   Brünnler, Tanja ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ACUTE PANCREATITIS; ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; PANCREAS NECROSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; APACHE; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PANCREATITIS; PANCREATITIS, ACUTE NECROTIZING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79955595788     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.503     Document Type: Article

References (49)

1. Hasibeder WR, Torgersen C, Rieger M et al. Critical care of the patient with acute pancreatitis. Anaesth Intensive Care 2009; 37: 190-206.
2. Mitchell RM, Byrne MF, Baillie J. Pancreatitis. Lancet 2003; 361: 1447-1455. (Pubitemid 36515050)
3. Charbonney E, Nathens AB. Severe acute pancreatitis: a review. Surg Infect (Larchmt) 2008; 9: 573-8.
4. Andersson R, Sward A, Tingstedt B et al. Treatment of acute pancreatitis: focus on medical care. Drugs 2009; 69: 505-514.
5. Evans AC, Papachristou GI, Whitcomb DC. Obesity and the risk of severe acute pancreatitis. Minerva Gastroenterol Dietol 2010; 56: 169-179.
6. Sandberg AA, Borgstrom A. Early prediction of severity in acute pancreatitis. Is this possible? JOP 2002; 3: 116-125. (Pubitemid 38963810)
7. Bradley EL III. A clinically based classification system for acute pancreatitis. Ann Chir 1993; 47: 537-541.
8. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829. (Pubitemid 15250137)
9. Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. Br J Surg 1990; 77: 1260-1264.
10. Johnson CD, Toh SK, Campbell MJ. Combination of APACHE-II score and an obesity score (APACHE-O) for the prediction of severe acute pancreatitis. Pancreatology 2004; 4: 1-6. (Pubitemid 38453116)
11. Ranson JH, Rifkind KM, Roses DF et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974; 139: 69-81.
12. Schroder T, Kivisaari L, Somer K et al. Significance of extrapancreatic findings in computed tomography (CT) of acute pancreatitis. Eur J Radiol 1985; 5: 273-5. (Pubitemid 16200211)
13. van den Biezenbos AR, Kruyt PM, Bosscha K et al. Added value of CT criteria compared to the clinical SAP score in patients with acute pancreatitis. Abdom Imaging 1998; 23: 622-6. (Pubitemid 28509592)
14. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology 2002; 223: 603-613. (Pubitemid 34547572)
15. Chatzicostas C, Roussomoustakaki M, Vardas E et al. Balthazar computed tomography severity index is superior to Ranson criteria and APACHE II and III scoring systems in predicting acute pancreatitis outcome. J Clin Gastroenterol 2003; 36: 253-260. (Pubitemid 36232638)
16. Balthazar EJ. Complications of acute pancreatitis: clinical and CT evaluation. Radiol Clin North Am 2002; 40: 1211-1227. (Pubitemid 35404050)
17. Johnson CD, Lempinen M, Imrie CW et al. Urinary trypsinogen activation peptide as a marker of severe acute pancreatitis. Br J Surg 2004; 91: 1027-1033. (Pubitemid 39070819)
18. Sultan S, Baillie J. What are the predictors of post-ERCP pancreatitis, and how useful are they? JOP 2002; 3: 188-194. (Pubitemid 38963808)
19. Neoptolemos JP, Kemppainen EA, Mayer JM et al. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet 2000; 355: 1955-1960. (Pubitemid 30326100)
20. Scholmerich J. Interleukins in acute pancreatitis. Scand J Gastroenterol Suppl 1996; 219: 37-42. (Pubitemid 126715326)
21. Mentula P, Kylanpaa ML, Kemppainen E et al. Early prediction of organ failure by combined markers in patients with acute pancreatitis. Br J Surg 2005; 92: 68-75. (Pubitemid 40144197)
22. Messmann H, Vogt W, Falk W et al. Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis. Eur J Gastroenterol Hepatol 1998; 10: 611-7. (Pubitemid 28330611)
23. Leser HG, Gross V, Scheibenbogen C et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101: 782-5.
24. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97: 1309-1318. (Pubitemid 34664770)
25. Wilson C, Heads A, Shenkin A et al. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 1989; 76: 177-181. (Pubitemid 19057020)
26. Gan SI, Romagnuolo J. Admission hematocrit: a simple, useful and early predictor of severe pancreatitis. Dig Dis Sci 2004; 49: 1946-1952. (Pubitemid 40228566)
27. Bakker OJ, van Santvoort HC, Besselink MG et al. Prevention, detection, and management of infected necrosis in severe acute pancreatitis. Curr Gastroenterol Rep 2009; 11: 104-110.
28. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2 : 103-111. (Pubitemid 40790157)
29. Schaffler A, Scholmerich J. The role of adiponectin in inflammatory gastrointestinal diseases. Gut 2009; 58: 317-322.
30. Schaffler A, Muller-Ladner U, Scholmerich J et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27 : 449-467. (Pubitemid 44213227)
31. Wozniak SE, Gee LL, Wachtel MS et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-1856.
32. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
33. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175. (Pubitemid 40193966)
34. Otero M, Lago R, Lago F et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295-301. (Pubitemid 40092403)
35. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447. (Pubitemid 38446357)
36. Schaffler A, Scholmerich J, Salzberger B. Adipose tissue as an immunological organ: toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol 2007; 28: 393-9. (Pubitemid 47385374)
37. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9; quiz 920.
38. Schaffler A, Landfried K, Volk M et al. Potential of adipocytokines in predicting peripancreatic necrosis and severity in acute pancreatitis: pilot study. J Gastroenterol Hepatol 2007; 22: 326-334. (Pubitemid 46238760)
39. Schaffler A. Serum resistin and leptin levels predict severity of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 418-9.
40. Schaffler A, Hamer O, Dickopf J et al. Admission resistin levels predict peripancreatic necrosis and clinical severity in acute pancreatitis. Am J Gastroenterol 2010; 105: 2474-2484.
41. Sommer G, Garten A, Petzold S et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008; 115: 13-23. (Pubitemid 351930789)
42. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
43. Samal B, Sun Y, Stearns G et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437.
44. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327. (Pubitemid 39069931)
45. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804-816. (Pubitemid 351959859)
46. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. (Pubitemid 46154646)
47. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49: 7-18. (Pubitemid 36078547)
48. Schutte K, Malfertheiner P. Markers for predicting severity and progression of acute pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22: 75-90.
49. Daniel P, Lesniowski B, Mokrowiecka A et al. Circulating levels of visfatin, resistin and pro-inflammatory cytokine interleukin-8 in acute pancreatitis. Pancreatology 2010; 10: 477-482.